JP2017535548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535548A5 JP2017535548A5 JP2017525946A JP2017525946A JP2017535548A5 JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5 JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017525946 A JP2017525946 A JP 2017525946A JP 2017535548 A5 JP2017535548 A5 JP 2017535548A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patient
- expression
- level
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079787P | 2014-11-14 | 2014-11-14 | |
| US62/079,787 | 2014-11-14 | ||
| PCT/US2015/059733 WO2016077227A2 (en) | 2014-11-14 | 2015-11-09 | Predicting response to a vegf antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017535548A JP2017535548A (ja) | 2017-11-30 |
| JP2017535548A5 true JP2017535548A5 (enExample) | 2018-12-20 |
Family
ID=54754748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525946A Pending JP2017535548A (ja) | 2014-11-14 | 2015-11-09 | Ｖｅｇｆアンタゴニストの応答の予測 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170226198A1 (enExample) |
| EP (1) | EP3218401B1 (enExample) |
| JP (1) | JP2017535548A (enExample) |
| KR (1) | KR20170082537A (enExample) |
| CN (1) | CN107106688A (enExample) |
| AR (1) | AR102647A1 (enExample) |
| AU (1) | AU2015346652A1 (enExample) |
| BR (1) | BR112017009633A2 (enExample) |
| CA (1) | CA2966216A1 (enExample) |
| HK (1) | HK1242996A1 (enExample) |
| IL (1) | IL251947A0 (enExample) |
| MX (1) | MX2017006201A (enExample) |
| RU (1) | RU2017120388A (enExample) |
| SG (1) | SG11201703744VA (enExample) |
| WO (1) | WO2016077227A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753984B (zh) * | 2018-08-28 | 2021-07-13 | 北京市神经外科研究所 | 预测或诊断脑恶性胶质瘤术后复发的生物标志物组合及其应用和试剂盒 |
| US20230340605A1 (en) * | 2020-02-04 | 2023-10-26 | Oslo Universitetssykehus Hf | Biomarkers predicting clinical response of a vegf-a inhibitory drug in cancer patients, method for their selection and use |
| CA3175129A1 (en) * | 2020-03-12 | 2021-09-19 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| CA3175127A1 (en) | 2020-03-12 | 2021-09-16 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4565240A1 (en) * | 2022-08-05 | 2025-06-11 | Geistlich Pharma AG | Combination therapy for treating cancers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2447695C (en) * | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| EP1435965A4 (en) * | 2001-09-26 | 2005-09-21 | Intermune Inc | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| AU2004215133B2 (en) * | 2003-02-27 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
| EP2583685A1 (en) * | 2004-06-10 | 2013-04-24 | Regeneron Pharmaceuticals, Inc. | Method of administering and using VEGF inhibitors for the treatment of human cancer |
| EP2321433A2 (en) * | 2008-08-29 | 2011-05-18 | F. Hoffmann-La Roche AG | Diagnostics and treatments for vegf-independent tumors |
| WO2011089101A1 (en) * | 2010-01-19 | 2011-07-28 | F. Hoffmann-La Roche Ag | Tumor tissue based biomarkers for bevacizumab combination therapies |
| SG10201401123VA (en) * | 2010-02-23 | 2014-08-28 | Genentech Inc | Anti-Angiogenesis Therapy For The Treatment Of Ovarian Cancer |
| CN104634971A (zh) * | 2010-07-19 | 2015-05-20 | 霍夫曼-拉罗奇有限公司 | 鉴定响应抗癌疗法的可能性升高的患者的方法 |
| CA2804350A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| EP2596364B1 (en) * | 2010-07-19 | 2015-12-16 | F.Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| KR20130124961A (ko) * | 2010-12-09 | 2013-11-15 | 에프. 호프만-라 로슈 아게 | 베바시주맙 병용 치료를 위한 마커로서의 agtr1 |
| US20140066393A1 (en) * | 2011-03-01 | 2014-03-06 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Servic | Method of selecting cancer patients for anti-angiogenesis therapy in combination with chemotherapy |
| SG11201402737SA (en) * | 2011-12-05 | 2014-06-27 | Hoffmann La Roche | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
-
2015
- 2015-11-09 HK HK18102570.4A patent/HK1242996A1/zh unknown
- 2015-11-09 CA CA2966216A patent/CA2966216A1/en not_active Abandoned
- 2015-11-09 AU AU2015346652A patent/AU2015346652A1/en not_active Abandoned
- 2015-11-09 WO PCT/US2015/059733 patent/WO2016077227A2/en not_active Ceased
- 2015-11-09 EP EP15802244.2A patent/EP3218401B1/en active Active
- 2015-11-09 BR BR112017009633A patent/BR112017009633A2/pt not_active IP Right Cessation
- 2015-11-09 RU RU2017120388A patent/RU2017120388A/ru not_active Application Discontinuation
- 2015-11-09 JP JP2017525946A patent/JP2017535548A/ja active Pending
- 2015-11-09 KR KR1020177013270A patent/KR20170082537A/ko not_active Withdrawn
- 2015-11-09 MX MX2017006201A patent/MX2017006201A/es unknown
- 2015-11-09 SG SG11201703744VA patent/SG11201703744VA/en unknown
- 2015-11-09 CN CN201580070085.3A patent/CN107106688A/zh active Pending
- 2015-11-13 AR ARP150103707A patent/AR102647A1/es unknown
-
2017
- 2017-04-26 IL IL251947A patent/IL251947A0/en unknown
- 2017-04-28 US US15/581,448 patent/US20170226198A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Singh et al. | TNBC: potential targeting of multiple receptors for a therapeutic breakthrough, nanomedicine, and immunotherapy | |
| JP2018508183A5 (enExample) | ||
| Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
| Battaglin et al. | The role of tumor angiogenesis as a therapeutic target in colorectal cancer | |
| Alese et al. | Update on emerging therapies for advanced colorectal cancer | |
| Clarke et al. | Understanding and targeting resistance to anti-angiogenic therapies | |
| Goldman et al. | Phase 1 dose‐escalation trial evaluating the combination of the selective MET (mesenchymal‐epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib | |
| Farley et al. | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study | |
| Nikolaou et al. | The role of neurotensin and its receptors in non-gastrointestinal cancers: A review | |
| Lim et al. | CDK4/6 inhibitors: promising opportunities beyond breast cancer | |
| Ayyappan et al. | Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer | |
| Ferté et al. | IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy | |
| Gilbert et al. | A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma | |
| RU2017125054A (ru) | Композиции и способы лечения и диагностики резистентного к химиотерапии рака | |
| Basu et al. | Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer | |
| Souglakos et al. | Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗ｉｇｆ−１ｒおよび抗ｅｒｂｂ３抗体の用法および用量 | |
| Aprile et al. | The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey | |
| Li et al. | Deguelin suppresses angiogenesis in human hepatocellular carcinoma by targeting HGF-c-Met pathway | |
| JP7579636B2 (ja) | 膵がん治療のための組み合わせ治療薬 | |
| Jeong et al. | Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer | |
| Shimizu et al. | Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer | |
| Petrillo et al. | Biomarkers for precision treatment in gastric cancer | |
| Tan et al. | New drug developments in metastatic gastric cancer | |
| Peng et al. | Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC |